Biokine Therapeutics

Company Overview

Snapshot

Founded in July 2000 by Prof. Amnon Peled, Biokine Therapeutics operates with 1-10 employees. The company has raised $1.95 million across 2 funding rounds from 2 investors. In October 2018, BioLineRx Ltd. increased its stake in Biokine's lead oncology platform, BL-8040, to 80%, involving a $10 million cash payment and $5 million in restricted BioLineRx shares, with additional milestone payments possible.

Business overview

Biokine Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel drugs for cancer treatment. The company's core technology involves identifying molecular and cellular mechanisms that regulate tumor development and metastasis. Its lead drug candidate, BKT140/BL8040, is a high-affinity CXCR4 antagonist currently undergoing clinical trials for refractory and relapsed acute myeloid leukemia (AML) and stem cell mobilization. Biokine Therapeutics operates within the Health Tech & Life Sciences sector, specifically targeting the Pharma & Medical Biotechnology and Drugs Discovery & Development industries, with a focus on patients and healthcare providers.

Strategic signal

In October 2018, BioLineRx Ltd. significantly increased its stake in. This transaction, valued at $15 million ($10 million upfront cash and $5 million in restricted shares), signals strong validation of Biokine's drug pipeline and its potential in the oncology market. For investors, this indicates a strategic move by a larger biopharmaceutical company to consolidate control over a promising asset, suggesting confidence in the future commercialization and clinical success of BL-8040.

Company Intelligence Q&A

What was a significant corporate development for Biokine Therapeutics in 2018?

In October 2018, BioLineRx Ltd. increased its stake in. This transaction included an upfront payment of $10 million in cash and $5 million in restricted BioLineRx shares, with potential for up to $5 million in future milestone payments. The $10 million upfront payment was financed through debt from Kreos Capital.

What clinical research collaboration did BioLineRx announce involving Biokine's product?

In September 2016, BioLineRx announced a clinical research collaboration with Genentech to investigate the combination of BL-8040 with Atezolizumab across multiple oncology indications. The collaboration involved Phase 1b studies to evaluate the clinical response, safety, and tolerability of this combination in hematologic malignancies and solid tumors.

What were the results of the Phase 2 trial for AML in 2016?

In March 2016, BioLineRx reported successful top-line results from its Phase 2 clinical trial for relapsed or refractory acute myeloid leukemia (AML). The company also identified a potential biomarker for future selection of BL-8040-responsive AML patients.

Did Biokine Therapeutics receive any grants for its cancer drug development?

In March 2009, Biokine Therapeutics received a $1.2 million research grant from the Office of the Chief Scientist of the Ministry of Industry, Trade and Labor. This funding supported a Phase I/IIa clinical study to test the safety and efficacy of its cancer drug, BKT140, initiated at the Sheba Medical Center.

Who were the investors in Biokine Therapeutics' January 2007 funding round?

In January 2007, Biokine Therapeutics received funding from investors including.